IgA and IgG Subclass Deficiencies
- Author: Terry W Chin, MD, PhD; Chief Editor: Harumi Jyonouchi, MD more...
Background
B cells are lymphocytes responsible for the production of antibody. The most common type of primary immunodeficiency (>50% of cases) involves deficient antibody production. Primary humoral deficiencies vary from complete absence of B cells, serum immunoglobulin (Ig), or both to lacunar deficits that involve specific antibody responses to polysaccharides. The spectrum of antibody deficiency is broad, ranging from decreased total IgG levels to normal IgG levels and from primary B-cell defects to combined immunodeficiencies with antibody abnormalities associated with other immune and often nonimmune abnormalities.
Although this article discusses agammaglobulinemia and hypogammaglobulinemia, the emphasis is on selective Ig deficiencies, including the decreased production of IgA and the various IgG subclasses and impaired antibody responses to polysaccharide antigens.
Pathophysiology
When IgA-bearing B lymphocytes fail to mature into IgA-secreting plasma cells, serum IgA levels are reduced, and specific IgA deficiency results. If B-cell development arrest leads to clinically significant decreases in or an absence of all Ig production, the result is agammaglobulinemia or hypogammaglobulinemia (see Agammaglobulinemia). Some, although reduced, numbers of IgA-bearing B cells are in the circulation, or IgA-bearing plasma cells are in the GI lamina propria in most cases with IgA deficiency. Failure of terminal B-cell differentiation is attributed to (1) an intrinsic B-cell defect, (2) inadequate or defective T-helper cells, (3) presence of or excessive IgA-specific T-cell suppressor cells, and (4) passage of maternal anti-IgA antibodies that suppress fetal IgA development.
In intrinsic B-cell defect, the alpha1 gene may be deleted along with other heavy-chain genes. Ig heavy-chain genes are located on chromosome 14q32 in the following order: 3'-XV-D-J-mu-delta-gamma1-psi/epsilon1-alpha1-psi/gamma1-gamma2-gamma4-epsilon-alpha2-5'. Therefore, homozygous deletions of large portions of the Ig heavy-chain locus result in individuals with complete absence of 3 or more Ig classes (IgG2, IgG4, IgA1, occasionally IgE). Investigators have described gene deletions of the heavy chain for Cƒ×1, Cƒ×2, Cƒ×4 and CƒÑ1 genes (in a patient with IgG1, IgG2, IgG4 and IgA1 deficiency) and Cƒ×2, Cƒ×4, CƒÕ, and CƒÑ1 genes (in patients with IgG2, IgG4, IgE, and IgA1 deficiencies). However, in general, the molecular mechanisms of IgG subclass deficiencies have not been clearly delineated.
Selective IgA deficiency is probably the most common of the primary immunodeficiency disorders, but it may also be asymptomatic. In 1993, Plebani et al described 2 siblings who appeared to be healthy and who did not have increased infections despite extensive deletion of immunoglobulin heavy chain locus.[1] They did have normal responses to immunization with protein and polysaccharide antigens. However, the authors did not measure secretory IgA.
Deficient secretory IgA with normal serum IgA levels is reported in few patients. Lack of severe infections in patients with IgA and secretory IgA deficiency may be attributed to compensatory increases in secretory IgM. Other concomitant immune defects may be required to increase the risk for respiratory and GI infections and various autoimmune diseases frequently described in patients with IgA deficiency. These concomitant immune defects may include deficiencies of certain IgG subclasses or of mannose-binding lectin (MBL).[2] The most common IgG-subclass deficiency associated with IgA deficiency is that of IgG2. IgA-IgG2 deficiency can also be seen with other IgG-subclass deficiencies, especially that involving IgG4.
The importance of IgG-subclass deficiency is reflected in the isotypes of IgG antibodies produced against microbial antigens. Antibodies against pneumococcal polysaccharide antigens are predominantly IgG2 and, to a lesser degree, IgG4. In contrast, antibodies against protein antigens, such as tetanus, are predominantly IgG1 and, to a lesser degree, IgG3. Finally, antibodies against large extracellular parasites, such as Schistosoma and Filaria organisms, exclusively belong to IgG4 subclass.[3]
This difference in isotypes of IgG antibodies may also extend to IgG antibodies against common dietary proteins, such as wheat (gliadin). Constantin et al (2005) found a difference in isotypes of antigliadin IgG antibodies in patients with celiac disease and those with IgE-mediated food allergy to wheat.[4]
Selective IgA deficiency is associated with an increased incidence of autoimmune and allergic diseases. This association may be due to increased exposure and subsequent sensitization with allergens due to the absence of secretory IgAs, which serve as blocking antibodies and which appear to have a role in tolerance induction.
Epidemiology
Frequency
United States
Selective IgA deficiency is the most common primary immunodeficiency, with a prevalence ranging from 1 in 223-1000 in community studies to 1 in 400-3000 in healthy blood donors. These various results may reflect differences in population selection or diagnostic criteria. To establish the diagnosis, some investigators use a serum IgA level of less than 5-10 mg/dL, whereas others used less than 2 standard deviations from age-appropriate control levels.
International
Large population studies in Czech Republic of more than 15,000 subjects revealed a IgA deficiency rate of 1 per 408, or 0.24%.[5]
The frequency of IgA deficiency in 7923 healthy whites in Austria revealed prevalence of IgA deficiency to be 0.21%, similar to the rate in the Czech study.[6] However, in this study, IgA deficiency was found predominantly in male subjects; it occurred in 1 woman and 14 men.
The prevalence of IgA deficiency in these studies appears to be similar to those reported in the United States.
Mortality/Morbidity
The risk for frequent and recurrent infections seems to be lower in patients with selective B-cell deficiency than in patients with agammaglobulinemia (patients who do not make any Ig). However, they have an increased risk of developing atopic or autoimmune diseases. Many patients have selective IgA or IgG subclass deficiency but remain asymptomatic. However, the clinician must be aware of any potential risk of atopic or autoimmune diseases to conduct careful monitoring. In patients with IgA and/or IgG subclass deficiency, treatment decisions depend on their clinical features (eg, the degree of their morbidity with infections and concomitant diseases). In general, IgA deficiency with concomitant immune defects such as defects in specific antibody production have higher rates of recurrent infections and bronchiectasis.[7, 8]
Individuals with selective IgA or IgG subclass deficiency are usually asymptomatic. However, patients with IgA-IgG2 deficiency frequently have recurrent and chronic sinopulmonary infections.
Data from many clinical studies suggest that patients with IgG subclass deficiency are particularly susceptible to various infections, but no direct cause-and-effect relationship has been established. This lack of data may be due to the difficulty of accurately measuring IgG subclass levels and to intravariability and intervariability of IgG subclass levels in individuals.
Patients with IgG subclass deficiency appear to have an increased incidence of asthma or sinusitis.
Although patients with deficiencies in IgA subclasses are usually asymptomatic, their incidence of allergic and autoimmune disorders appears to be high. Therefore, treatment of the associated medical conditions must be considered.
Race
Individuals of Finnish descent may have the highest frequency of IgA deficiency. IgA deficiency also appears to be more prevalent in blacks than whites, whereas Asians have the lowest incidence. IgA deficiency is associated with defects of other Igs, especially those of the IgG subclass, with a high frequency. IgG2 deficiency is reported in 19% and 8% of Swedish and American patients with IgA deficiency, respectively.
Sex
Most studies of healthy individuals without medical concerns reveal no sex predilection. However, one study showed an elevated prevalence of IgA deficiency in hospitalized male patients. In studies of healthy whites in Austria, the prevalence of IgA deficiency was also increased in male subjects.
Age
Most selective IgA or IgG subclass deficiencies manifesting with clinical symptoms are detected during early childhood. The frequency and severity of infections decrease as patients' age, and their quantitative Ig levels may increase. Indeed, patients with IgA deficiency may compensate over time with increased IgG1 and IgG3 antibody levels. On the contrary, some patients initially identified as having IgG2 and IgA deficiency may progress to have typical common variable immunodeficiency (CVID) with panhypogammaglobulinemia. Slyper and Pietryga (1997) described a patient with chromosomal deletion (18q-) who initially had IgA deficiency but subsequently developed CVID.[9]
Plebani A, Ugazio AG, Meini A, et al. Extensive deletion of immunoglobulin heavy chain constant region genes in the absence of recurrent infections: when is IgG subclass deficiency clinically relevant?. Clin Immunol Immunopathol. Jul 1993;68(1):46-50. [Medline].
Santaella ML, Peredo R, Disdier OM. IgA deficiency: clinical correlates with IgG subclass and mannan-binding lectin deficiencies. P R Health Sci J. Jun 2005;24(2):107-10. [Medline].
Anantaphruti MT, Nuamtanong S, Dekumyoy P. Diagnostic values of IgG4 in human gnathostomiasis. Trop Med Int Health. Oct 2005;10(10):1013-21. [Medline].
Constantin C, Huber WD, Granditsch G, et al. Different profiles of wheat antigens are recognised by patients suffering from coeliac disease and IgE-mediated food allergy. Int Arch Allergy Immunol. Nov 2005;138(3):257-66. [Medline].
Litzman J, Sevcikova I, Stikarovska D, et al. IgA deficiency in Czech healthy individuals and selected patient groups. Int Arch Allergy Immunol. Oct 2000;123(2):177-80. [Medline].
Weber-Mzell D, Kotanko P, Hauer AC, et al. Gender, age and seasonal effects on IgA deficiency: a study of 7293 Caucasians. Eur J Clin Invest. Mar 2004;34(3):224-8. [Medline].
Aghamohammadi A, Cheraghi T, Gharagozlou M, et al. IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol. Jan 2009;29(1):130-6. [Medline].
Aghamohammadi A, Mohammadi J, Parvaneh N, et al. Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol. 2008;147(2):87-92. [Medline].
Slyper AH, Pietryga D. Conversion of selective IgA deficiency to common variable immunodeficiency in an adolescent female with 18q deletion syndrome. Eur J Pediatr. Feb 1997;156(2):155-6. [Medline].
Cunningham-Rundles C, Brandeis WE, Pudifin DJ, et al. Autoimmunity in selective IgA deficiency: relationship to anti-bovine protein antibodies, circulating immune complexes and clinical disease. Clin Exp Immunol. Aug 1981;45(2):299-304. [Medline].
Jeurissen A, Moens L, Raes M, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens. Clin Chem. Mar 2007;53(3):505-10. [Medline].
Tuerlinckx D, Vermeulen F, Pekus V, et al. Optimal assessment of the ability of children with recurrent respiratory tract infections to produce anti-polysaccharide antibodies. Clin Exp Immunol. Aug 2007;149(2):295-302. [Medline].
Boyle RJ, Le C, Balloch A, et al. The clinical syndrome of specific antibody deficiency in children. Clin Exp Immunol. Dec 2006;146(3):486-92. [Medline].
van Kessel DA, van Velzen-Blad H, van den Bosch JM, et al. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J. Mar 2005;25(3):482-9. [Medline].
Vendrell M, de Gracia J, Rodrigo MJ, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest. Jan 2005;127(1):197-204. [Medline].
Wiertsema SP, Veenhoven RH, Sanders EA, et al. Immunologic screening of children with recurrent otitis media. Curr Allergy Asthma Rep. Jul 2005;5(4):302-7. [Medline].
Cheng YK, Decker PA, O'Byrne MM, et al. Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome. Ann Allergy Asthma Immunol. Sep 2006;97(3):306-11. [Medline].
Costa Carvalho BT, Nagao AT, Arslanian C, et al. Immunological evaluation of allergic respiratory children with recurrent sinusitis. Pediatr Allergy Immunol. Sep 2005;16(6):534-8. [Medline].
Mrabet-Dahbi S, Breuer K, Klotz M, et al. Deficiency in immunoglobulin G2 antibodies against staphylococcal enterotoxin C1 defines a subgroup of patients with atopic dermatitis. Clin Exp Allergy. Mar 2005;35(3):274-81. [Medline].
Gregorek H, Dzierzanowska-Fangrat K, Woynarowski M, et al. Persistence of HBV-DNA in children with chronic hepatitis B who seroconverted to anti-HBs antibodies after interferon-alpha therapy: correlation with specific IgG subclass responses to HBsAg. J Hepatol. Apr 2005;42(4):486-90. [Medline].
de Laat PC, Weemaes CM, Bakkeren JA, et al. Familial selective IgA deficiency with circulating anti-IgA antibodies: a distinct group of patients?. Clin Immunol Immunopathol. Jan 1991;58(1):92-101. [Medline].
Schaffer FM. Clinical assessment and management of abnormal IgA levels. Ann Allergy Asthma Immunol. Mar 2008;100(3):280-2. [Medline].
Toptygina AP, Pukhalsky AL, Alioshkin VA. Immunoglobulin G subclass profile of antimeasles response in vaccinated children and in adults with measles history. Clin Diagn Lab Immunol. Jul 2005;12(7):845-7. [Medline].
Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol. Nov 2007;99(5):462-4. [Medline].
Rezaei N, Aghamohammadi A, Siadat SD, et al. Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies. Vaccine. Jul 20 2007;25(29):5308-14. [Medline].
Kamchaisatian W, Wanwatsuntikul W, Sleasman JW, et al. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. J Allergy Clin Immunol. Dec 2006;118(6):1336-41. [Medline].
Garside JP, Kerrin DP, Brownlee KG, et al. Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic. Pediatr Pulmonol. Feb 2005;39(2):135-40. [Medline].
Ozkan H, Atlihan F, Genel F, et al. IgA and/or IgG subclass deficiency in children with recurrent respiratory infections and its relationship with chronic pulmonary damage. J Investig Allergol Clin Immunol. 2005;15(1):69-74. [Medline].
Kutukculer N, Karaca NE, Demircioglu O, et al. Increases in serum immunoglobulins to age-related normal levels in children with IgA and/or IgG subclass deficiency. Pediatr Allergy Immunol. Mar 2007;18(2):167-73. [Medline].
Cohn JA, Skorpinski E, Cohn JR. Prevention of pneumococcal infection in a patient with normal immunoglobulin levels but impaired polysaccharide antibody production. Ann Allergy Asthma Immunol. Nov 2006;97(5):603-5. [Medline].
Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J. Aug 1998;17(8):685-91. [Medline].
Meyts I, Bossuyt X, Proesmans M, et al. Isolated IgG3 deficiency in children: to treat or not to treat? Case presentation and review of the literature. Pediatr Allergy Immunol. Nov 2006;17(7):544-50. [Medline].
Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am. Nov 2008;28(4):833-49, ix. [Medline].
Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am. Nov 2008;28(4):765-78, viii. [Medline].
Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy. Nov 2005;25(11 Pt 2):78S-84S. [Medline].
Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm. Aug 15 2005;62(16 Suppl 3):S5-11. [Medline].
Sorensen RU, Leiva LE, Javier FC 3rd, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. Aug 1998;102(2):215-21. [Medline].
Lawton AR. IgG subclass deficiency and the day-care generation. Pediatr Infect Dis J. May 1999;18(5):462-6. [Medline].
Wolpert J, Knutsen AP. Natural history of selective antibody deficiency to bacterial polysaccharide antigens in children. Pediatr Asthma Allergy Immunol. 1998;12:183-91.
al-Attas RA, Rahi AH. Primary antibody deficiency in Arabs: first report from eastern Saudi Arabia. J Clin Immunol. Sep 1998;18(5):368-71. [Medline].
Buehring I, Friedrich B, Schaaf J, et al. Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies. Clin Exp Immunol. Sep 1997;109(3):468-72. [Medline].
Farhoudi A, Aghamohammadi A, Moin M, et al. Distribution of primary immunodeficiency disorders diagnosed in the Children's Medical Center in Iran. J Investig Allergol Clin Immunol. 2005;15(3):177-82. [Medline].
Feydy A, Sibilia J, De Kerviler E, et al. Chest high resolution CT in adults with primary humoral immunodeficiency. Br J Radiol. Dec 1996;69(828):1108-16. [Medline].
Gogorcena MA, Castillo M, Casajuana J, et al. Accessibility to primary health care centers: experience and evaluation of an appointment system program. Qual Assur Health Care. Mar 1992;4(1):33-41. [Medline].
Kainulainen L, Nikoskelainen J, Vuorinen T, et al. Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia. Am J Respir Crit Care Med. Apr 1999;159(4 Pt 1):1199-204. [Medline].
Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. Nov 1999;104(5):1031-6. [Medline].
Kavanaugh AF, Huston DP. Variable expression of IgG2 deficiency. J Allergy Clin Immunol. Jul 1990;86(1):4-10. [Medline].
Kuijpers TW, Weening RS, Out TA. IgG subclass deficiencies and recurrent pyogenic infections, unresponsiveness against bacterial polysaccharide antigens. Allergol Immunopathol (Madr). Jan-Feb 1992;20(1):28-34. [Medline].
Mila J, Matamoros N, Pons de Ves J, et al. [The Spanish Registry of Primary Immunodeficiencies. REDIP-1998]. Sangre (Barc). Apr 1999;44(2):163-7. [Medline].
Papadopoulou A, Mermiri D, Taousani S, et al. Bronchial hyper-responsiveness in selective IgA deficiency. Pediatr Allergy Immunol. Sep 2005;16(6):495-500. [Medline].
Schaffer FM, Palermos J, Zhu ZB, et al. Individuals with IgA deficiency and common variable immunodeficiency share polymorphisms of major histocompatibility complex class III genes. Proc Natl Acad Sci U S A. Oct 1989;86(20):8015-9. [Medline].
Shackelford PG. IgG subclasses: importance in pediatric practice. Pediatr Rev. Aug 1993;14(8):291-6. [Medline].
Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child. Jun 1996;74(6):527-30. [Medline].
Soderstrom T, Soderstrom R, Enskog A. Immunoglobulin subclasses and prophylactic use of immunoglobulin in immunoglobulin G subclass deficiency. Cancer. Sep 15 1991;68(6 Suppl):1426-9. [Medline].
Stiehm ER, Casillas AM, Finkelstein JZ, et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol. Jun 1998;101(6 Pt 1):848-9. [Medline].
Wilton AN, Cobain TJ, Dawkins RL. Family studies of IgA deficiency. Immunogenetics. 1985;21(4):333-42. [Medline].
| Brand(Manufacturer) | Manufacturing Process | pH | Additives (IVIg products containing sucrose are most often associated with renal dysfunction, acute renal failure, and osmotic nephrosis, particularly with preexisting risk factors [eg, history of renal insufficiency, diabetes mellitus, age >65 y, dehydration, sepsis, paraproteinemia, nephrotoxic drugs]) | Parenteral Form and Final Concentrations | IgA Content mcg/mL |
| Carimune NF (CSL Behring) | Kistler-Nitschmann fractionation; pH 4, nanofiltration | 6.4-6.8 | 6% solution: 10% sucrose, < 20 mg NaCl/g protein | Lyophilized powder 3%, 6%, 9%, 12% | Trace |
| Flebogamma (Grifols USA) | Cohn-Oncley fractionation, PEG precipitation, ion-exchange chromatography, pasteurization | 5.1-6 | Sucrose free, contains 5% D-sorbitol | Liquid 5% | < 50 |
| Gammagard Liquid 10% (Baxter Bioscience) | Cohn-Oncley cold ethanol fractionation, cation and anion exchange chromatography, solvent detergent treated, nanofiltration, low pH incubation | 4.6-5.1 | 0.25M glycine | Ready-for-use Liquid 10% | 37 |
| Gamunex (Talecris Biotherapeutics) | Cohn-Oncley fractionation, caprylate-chromatography purification, cloth and depth filtration, low pH incubation | 4-4.5 | Does not catain carbohydrate stabilizers (eg, sucrose, maltose), contains glycine | Liquid 10% | 46 |
| Gammaplex (Bio Products) | Solvent/detergent treatment targeted to enveloped viruses; virus filtration using Pall Ultipor to remove small viruses including nonenveloped viruses; low pH incubation | 4.8-5.1 | Contains sorbitol (40 mg/mL); do not administer if fructose intolerant | Ready-for-use solution 5% | < 10 |
| Iveegam EN (Baxter Bioscience) | Cohn-Oncley fraction II/III; ultrafiltration; pasteurization | 6.4-7.2 | 5% solution: 5% glucose, 0.3% NaCl | Lyophilized powder 5% | < 10 |
| Polygam S/D Gammagard S/D (Baxter Bioscience for the American Red Cross) | Cohn-Oncley cold ethanol fractionation, followed by ultracentrafiltration and ion exchange chromatography; solvent detergent treated | 6.4-7.2 | 5% solution: 0.3% albumin, 2.25% glycine, 2% glucose | Lyophilized powder 5%, 10% | < 1.6 (5% solution) |
| Octagam (Octapharma USA) 9/24/10: Withdrawn from market because of unexplained reports of thromboembolic events | Cohn-Oncley fraction II/III; ultrafiltration; low pH incubation; S/D treatment pasteurization | 5.1-6 | 10% maltose | Liquid 5% | 200 |
| Panglobulin (Swiss Red Cross for the American Red Cross) | Kistler-Nitschmann fractionation; pH 4 incubation, trace pepsin, nanofiltration | 6.6 | Per gram of IgG: 1.67 g sucrose, < 20 mg NaCl | Lyophilized powder 3%, 6%, 9%, 12% | 720 |
| Privigen Liquid 10% (CSL Behring) | Cold ethanol fractionation, octanoic acid fractionation, and anion exchange chromatography; pH 4 incubation and depth filtration | 4.6-5 | L-proline (approximately 250 mmol/L) as stabilizer; trace sodium; does not contain carbohydrate stabilizers (eg, sucrose, maltose) | Ready-for use liquid 10% | < 25 |
Print
